FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094705824> ?p ?o ?g. }

• W3094705824 endingPage "26" @default.
• W3094705824 startingPage "24" @default.
• W3094705824 abstract "Background The SARS CoV-2 / COVID 19 pandemic has challenged the world's health systems, especially services that treat cancer. The first studies in China showed that cancer patients had a higher risk of becoming infected and dying. Other risk factors for mortality were age over 65 years, male sex, the presence of comorbidity, hypertension, cardiovascular disease, diabetes, and obesity. Data on the specific behavior of patients with multiple myeloma (MM) in the pandemic are scarce. The mechanisms by which MM patients may have a higher mortality are multiple, derived both from the disease itself due to cellular and humoral immunity deficiency as well as from anti-myeloma treatment. The present study aims to establish the behavior of the disease in the pandemic period in Latin America. Methods This is a retrospective case series of in and outpatients with a diagnosis of MM and COVID-19 reported from centers from Latin America between March and July 31, 2020. The analysis of demographic, clinical, laboratory, complications and therapy variables were done using descriptive statistics. A Kaplan Meier survival analysis was performed, with Log Rank statistic. Finally, a Cox regression was performed to identify independent risk factors of worse outcome. Pre-admission characteristics, MM status, and comorbidities constituted the reference model and were used to adjust the association of relevant MM characteristics with mortality. Program used for analysis was SPSS statistics 25. Results Fifty-two patients with COVID-19 and MM from 7 countries were included. Demographic characteristics, comorbidities, infection baseline clinical conditions, treatment, and outcomes are shown in Table 1. The characteristics in terms of MM status are shown in Table 2. When performing the survival analysis, it is evidenced that the survival of the entire cohort at day 49 was 67% Figure 1. When we focus on patients with comorbidities, survival drops to 53.5% +/- 10.6 (CI 95% 53.4 - 99.4 and p value of 0.041) for the same day Figure 2. When performing the obesity analysis, a drop in survival of up to 39% was observed (95% CI 24.448 - 56.76, with p = 0.00001) Figure 3. Adjusted HR for obesity is 5,078 (95% CI 1,389-18,558, α0.014) and mechanical ventilation with a HR of 3,943 (95% CI - 1,296 - 11,998, α0.016) When comparing patients with controlled MM (&gt; PR) versus uncontrolled, the mortality rate was 84% versus 58% respectively (p = 0.109). Comorbidities (presence of either diabetes, arterial hypertension, cardiovascular disease, or others), obesity, need of mechanical ventilation, and &lt;VGPR at the time of infection were independent factors of lower survival Table 3. Conclusions Patients with MM and COVID-19 has an overall mortality of approximately 30% and this is strongly influenced by the presence of comorbidities, uncontrolled disease and need of mechanical ventilation. Survival of patients without comorbidities and controlled disease is good, suggesting that this group of patients would not require modification of MM therapy. The main limitations of our study are its retrospective nature and the low number of patients. It must be highlighted that at the time of the analysis most of Latin American countries were still in the peak of the pandemic. Prospective studies are required to elucidate the behavior of these risk factors in mortality, to optimize the management of patients with MM in this period of the SARS CoV-2 / COVID-19 pandemic. Disclosures Peña: BindingSite: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sandoz: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Amgen: Speakers Bureau. Abello:Novartis: Consultancy, Honoraria; Amgen: Consultancy, Research Funding; Takeda: Honoraria, Research Funding; Dr. Reddy's: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding. Idrobo:Abbvie: Honoraria, Speakers Bureau; Tecnofarma: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Amgen: Honoraria, Speakers Bureau. Rojas:Novartis: Consultancy; Roche: Honoraria; Sandoz: Honoraria; Abbvie: Honoraria. Remaggi:Takeda: Honoraria; Raffo Argentina: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Gador Argentina: Research Funding; Amgen: Honoraria, Research Funding. Alvarado:Celgene: Speakers Bureau; Alexion: Speakers Bureau; Amgen: Speakers Bureau; Novartis: Speakers Bureau; Roche: Speakers Bureau. De la Peña-Celaya:Amgen: Speakers Bureau; Janssen: Speakers Bureau; Novartis: Speakers Bureau. Perez:Novartis: Speakers Bureau; Celgene: Speakers Bureau; Roche: Speakers Bureau." @default.
• W3094705824 created "2020-11-09" @default.
• W3094705824 creator A5000184436 @default.
• W3094705824 creator A5001184015 @default.
• W3094705824 creator A5007631255 @default.
• W3094705824 creator A5013934484 @default.
• W3094705824 creator A5015223456 @default.
• W3094705824 creator A5017612626 @default.
• W3094705824 creator A5019507572 @default.
• W3094705824 creator A5022296159 @default.
• W3094705824 creator A5025847424 @default.
• W3094705824 creator A5027096545 @default.
• W3094705824 creator A5031078985 @default.
• W3094705824 creator A5034141362 @default.
• W3094705824 creator A5034565266 @default.
• W3094705824 creator A5036090957 @default.
• W3094705824 creator A5044275228 @default.
• W3094705824 creator A5044657982 @default.
• W3094705824 creator A5045799991 @default.
• W3094705824 creator A5047233161 @default.
• W3094705824 creator A5050803071 @default.
• W3094705824 creator A5052888569 @default.
• W3094705824 creator A5053353540 @default.
• W3094705824 creator A5068099446 @default.
• W3094705824 creator A5068844567 @default.
• W3094705824 creator A5069814716 @default.
• W3094705824 creator A5071716797 @default.
• W3094705824 creator A5072571581 @default.
• W3094705824 creator A5081488322 @default.
• W3094705824 date "2020-11-05" @default.
• W3094705824 modified "2023-10-17" @default.
• W3094705824 title "Sars Cov-2/COVID-19 in Multiple Myeloma Latin-American Patients <i>COVID-Lamm Study on Behalf of Gelamm (</i> <i>Grupo de Estudio Latino- Americano de Mieloma Múltiple</i> <i>)</i>" @default.
• W3094705824 doi "https://doi.org/10.1182/blood-2020-142823" @default.
• W3094705824 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8330368" @default.
• W3094705824 hasPublicationYear "2020" @default.
• W3094705824 type Work @default.
• W3094705824 sameAs 3094705824 @default.
• W3094705824 citedByCount "0" @default.
• W3094705824 crossrefType "journal-article" @default.
• W3094705824 hasAuthorship W3094705824A5000184436 @default.
• W3094705824 hasAuthorship W3094705824A5001184015 @default.
• W3094705824 hasAuthorship W3094705824A5007631255 @default.
• W3094705824 hasAuthorship W3094705824A5013934484 @default.
• W3094705824 hasAuthorship W3094705824A5015223456 @default.
• W3094705824 hasAuthorship W3094705824A5017612626 @default.
• W3094705824 hasAuthorship W3094705824A5019507572 @default.
• W3094705824 hasAuthorship W3094705824A5022296159 @default.
• W3094705824 hasAuthorship W3094705824A5025847424 @default.
• W3094705824 hasAuthorship W3094705824A5027096545 @default.
• W3094705824 hasAuthorship W3094705824A5031078985 @default.
• W3094705824 hasAuthorship W3094705824A5034141362 @default.
• W3094705824 hasAuthorship W3094705824A5034565266 @default.
• W3094705824 hasAuthorship W3094705824A5036090957 @default.
• W3094705824 hasAuthorship W3094705824A5044275228 @default.
• W3094705824 hasAuthorship W3094705824A5044657982 @default.
• W3094705824 hasAuthorship W3094705824A5045799991 @default.
• W3094705824 hasAuthorship W3094705824A5047233161 @default.
• W3094705824 hasAuthorship W3094705824A5050803071 @default.
• W3094705824 hasAuthorship W3094705824A5052888569 @default.
• W3094705824 hasAuthorship W3094705824A5053353540 @default.
• W3094705824 hasAuthorship W3094705824A5068099446 @default.
• W3094705824 hasAuthorship W3094705824A5068844567 @default.
• W3094705824 hasAuthorship W3094705824A5069814716 @default.
• W3094705824 hasAuthorship W3094705824A5071716797 @default.
• W3094705824 hasAuthorship W3094705824A5072571581 @default.
• W3094705824 hasAuthorship W3094705824A5081488322 @default.
• W3094705824 hasBestOaLocation W30947058241 @default.
• W3094705824 hasConcept C10515644 @default.
• W3094705824 hasConcept C107130276 @default.
• W3094705824 hasConcept C121608353 @default.
• W3094705824 hasConcept C126322002 @default.
• W3094705824 hasConcept C144024400 @default.
• W3094705824 hasConcept C149923435 @default.
• W3094705824 hasConcept C187316915 @default.
• W3094705824 hasConcept C2776364478 @default.
• W3094705824 hasConcept C2779134260 @default.
• W3094705824 hasConcept C2779159551 @default.
• W3094705824 hasConcept C3008058167 @default.
• W3094705824 hasConcept C50382708 @default.
• W3094705824 hasConcept C524204448 @default.
• W3094705824 hasConcept C71924100 @default.
• W3094705824 hasConcept C89623803 @default.
• W3094705824 hasConceptScore W3094705824C10515644 @default.
• W3094705824 hasConceptScore W3094705824C107130276 @default.
• W3094705824 hasConceptScore W3094705824C121608353 @default.
• W3094705824 hasConceptScore W3094705824C126322002 @default.
• W3094705824 hasConceptScore W3094705824C144024400 @default.
• W3094705824 hasConceptScore W3094705824C149923435 @default.
• W3094705824 hasConceptScore W3094705824C187316915 @default.
• W3094705824 hasConceptScore W3094705824C2776364478 @default.
• W3094705824 hasConceptScore W3094705824C2779134260 @default.
• W3094705824 hasConceptScore W3094705824C2779159551 @default.
• W3094705824 hasConceptScore W3094705824C3008058167 @default.
• W3094705824 hasConceptScore W3094705824C50382708 @default.
• W3094705824 hasConceptScore W3094705824C524204448 @default.
• W3094705824 hasConceptScore W3094705824C71924100 @default.
• W3094705824 hasConceptScore W3094705824C89623803 @default.
• W3094705824 hasIssue "Supplement 1" @default.

• next